Peptides News and Research

RSS

immatics initiates IMA901 Phase III trial in renal cell carcinoma

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma.

15 Jun 2011

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST cTnI-II diagnostic test, clearing the way for its sale in the United States.

14 Jun 2011

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

The novel cardiac biomarker ST2 was highlighted in a presentation at last month's 2011 Heart Failure Congress of the European Society of Cardiology in Gothenburg, Sweden. As this study and others have demonstrated, a patient's ST2 level can help a physician better predict prognosis in ambulatory, chronic heart failure patients, which can allow physicians to more appropriately tailor care.

10 Jun 2011

Integromics launches OmicsHub Proteomics 2.0

Integromics, a market leader in IT solutions provision for life sciences in the field of genomics and proteomics, today announces the availability of OmicsHub(R) Proteomics 2.0, a new version of the OmicsHub product adding several new features to its existing centralized data management and analysis capabilities for mass spectrometry laboratories and core facilities.

8 Jun 2011

Therapeutic equivalent to replace penicillin

Antibiotics are among the greatest achievements of medical science. But lately the former multi-purpose weapon fails in the battle against infectious diseases. Bacteria are increasingly developing resistance to antibiotics. Researchers have now found a therapeutic equivalent which could replace penicillin and related phamaceuticals.

8 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

Scientists find neuronal cells die in Alzheimer's disease

In what they are calling a new direction in the study of Alzheimer's disease, UC Santa Barbara scientists have made an important finding about what happens to brain cells that are destroyed in Alzheimer's disease and related dementias.

8 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Scientists at Queen's University Belfast have discovered proteins in frog skins which could be used to treat cancer, diabetes, stroke and transplant patients by regulating the growth of blood vessels.

7 Jun 2011

Bruker to introduce unique CaptiveSpray ion source for proteomics at ASMS 2011

At ASMS 2011, Bruker is introducing the breakthrough, proprietary CaptiveSpray electrospray ion source for nano-HPLC applications in proteomics. Using CaptiveSpray technology in many cases increases bottom-up protein identifications significantly, and CaptiveSpray is presently the best available technology for robust, reproducible protein ID or quantitative proteomics applications, with excellent, stable sensitivity over long time periods

6 Jun 2011

Researchers discover a peptide that short circuits chronic pain pathway

Researchers at the Indiana University School of Medicine have discovered a peptide that short circuits a pathway for chronic pain. Unlike current treatments this peptide does not exhibit deleterious side effects such as reduced motor coordination, memory loss, or depression, according to an article in Nature Medicine posted online June 5, 2011.

6 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

Diamyd European Phase III study in diabetes does not meet primary endpoint

Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

Researchers find mechanism of action for cancer-killing peptides

Researchers from Aalto University have found the mechanism of action for cancer-cell-killing peptides. This breakthrough is expected to lead to better medication, in particular better treatments for leukemia, skin cancer, and infections caused by multi-resistant bacteria.

27 May 2011

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.

25 May 2011

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

PolyPid, a developer of innovative drug carriers, announced today the company’s flagship platform – PolyPid. PolyPid is a new, innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems. The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, protein and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

Peptides News and Research

immatics initiates IMA901 Phase III trial in renal cell carcinoma

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

Integromics launches OmicsHub Proteomics 2.0

Therapeutic equivalent to replace penicillin

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

Scientists find neuronal cells die in Alzheimer's disease

LLS announces four new Academic Concierge partnerships for cancer drug development

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Bruker to introduce unique CaptiveSpray ion source for proteomics at ASMS 2011

Researchers discover a peptide that short circuits chronic pain pathway

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Cancer vaccine shows improved response rate in patients

Scientists uncover new therapeutic target that could prevent stress-related cell death

Diamyd European Phase III study in diabetes does not meet primary endpoint

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers find mechanism of action for cancer-killing peptides

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News